Sorry if I mistook you for Bankerboy. You undoubted must have a prestigious background in biomed stocks. I just got confused because you've come off as such a jerk. You must be really smart and a really good researcher and so super busy doing important things to justify you being so arrogant! I won't waste any more of your time.
mkeeryfuller: You remind me of someone i know: Bankerboy, Bigbuffoon, Coldcoffee, & Bigbang. Your new alias' theme is the arrogant PhD with a chip on his shoulder routine, utterly disgusted with people more successful than himself. Good one.
jpcalm: Excellent post! I think I am asking the right questions and I hope your answers are correct! I don't think we should become complacent. Placing greater trust in David Lowe than Robert Stern is probably the right choice, but not by much. AMBS is in a good place with LymPro, no doubt, but there are landmines in the terrain we have yet to travel. (Further testing to be done, Reimbursement, FDA approval, etc) That's the case with all pioneering, but I'd rather be here than in Georgetown's place.
"I came not to send peace but a sword." I'm doing what Jesus would do; he was about the truth, even when that was painful. I'm just sorting through it all to find the truth.
jegfsu: I basically agree with you...but I'm still going to ask the questions. The kitchen needs to be a hot place for shareholders....and management. Without raising questions to make them accountable management might get sloppy. Nothing is a sure deal in any stock. I love my investment in AMBS, but I'm not going to back off asking questions!!
Thank you, muta, a fellow truth seeker. Your quote above is the most accurate assessment of 2015 potential LymPro revenues, but it lacks any kind of specificity. We often throw around the 500 million revenue per year figure once we get FDA approval, but we have not idea how much CLIA will allow us to generate in the mean time. And, with Dr. Stern's contradictory comment about FDA approval being much further off,in his opinion, pinning down our revenues under CLIA seems like a reasonable question.
Gerald didn't say CLIA regulations prevented him from giving us LymPro data. Another shareholder had to ask if that was the reason. As for our having a partner for LymPro...I missed that. I read "We are in a position to initiate the partnering process in the first quarter." I'm not sure that sentence means they have found a partner, I think it means they have begun looking for one. It's not very clear....;is it? Do you know what kind of revenue we might receive under CLIA in 2015? 50 million? 20 million? 2 million? I don't think it's ever been disclosed by management. I don't think anyone has even asked management. But I just have. I hope that doesn't offend anyone. I think these things are worth knowing as shareholders.
bif: I am not here for followers. I am here to invest and make money. I am seeking for much more clarification than management has given. I don't expect everyone to agree with me. That is fine. I am not a trader of AMBS, I am a long and the way I do my DD is to raise questions. That is what I do. Sometimes it is better to disturb people in the pursuit of truth than to just rely on past assumptions and hope everything works out. This mb needs honest debate about all the issues affecting our investment. I wish the bashers would leave...they are just greedy longs. But those who just repeat the same old mantras about how rich we'll soon be...need to sober up and confront reality. I hope to be rich soon, too. My questions are designed to find out how soon I'll be rich, or whether those dreams are still far off, or heaven forbid...far fetched!
hulk: what post did your read? I said we are "Pioneering" LymPro. That has both good and bad aspects to it. I am just trying to stay informed as LymPro is IMHO, an important piece of the AMBS puzzle over the next 6 to 12 months.
Dr. Robert Stern's statement that no AD blood test would be available (FDA approval) for 5 to 10 years makes it sound like LymPro's regulatory path to FDA approval is based on theory and assumptions, after all, no other blood test has EVER been FDA approved for AD. We are pioneering LymPro! That is the good news....and the bad news. The good news is IF we gain access through CLIA to commercialization and it catches on to the point the FDA gives us approval for more widespread use...then LymPro and AMBS and us shareholders will win the lottery!! The bad news is: there may be unforeseen obstacles in our path that may impede LymPro's progress. For example, this HR4303 bill that just passed, how will that affect reimbursement for LymPro? There is much we as shareholders simply don't know about LymPro's path to the huge AD market...some of it is based on assumption and theory. We are pioneering. The more management enlightens us, the better.
jpcalm: I have been looking for more openness about LymPro and MANF and Phenoguard. I understand that when negotiations are really hot an NDA is appropriate. But Gerald seems to use the "NDA" umbrella for everything...all the time. At some point, people need to know what is going on, and not in a cryptic subtle way, but out in the open. That is what I need. The company has said nothing about MANF/Diabetes. A month ago he said we'd be getting an update on diabetes data soon. That is an example of something i am looking for. We didn't get data on the LymPro update, but that has been explained why not. Gerald tells us we are on target for commercialization in 2014, but Dr. Stern's comments about FDA approval are worrisome about how fast LymPro will be able to ramp up under CLIA. Maybe Gerald doesn't know? He has never given ball park estimates of LymPro's potential revenue opportunities under CLIA: 50 million in 2015? 20 million in 2015? 2 million in 2015? Will FDA approval likely happen in 2016? or 2020? JP: share with us why you don't share these same concerns about LymPro. We'd appreciate your opinion.
bothshallrow: Both Gerald and Dr. Lowe have recently confirmed that LymPro is on target to be commercialized before the end of 2014. But, Dr. Stern's statement, even with Gerald's explanation, is troubling for me. Management seems to have not only kept the media in the dark about LymPro, but experts in the AD field as well!! I hope that strategy pays off. I was disappointed we didn't get concrete data in Gerald's LymPro update. Then, a couple days later someone posted a CLIA regulation that prohibits data from being made public until all the CLIA testing is complete. I wish Gerald has let us know that, that would have eased some of our concerns. Gerald's talk about a LymPro partner has also been "coy." "We are in a position to initiate the partnering process in the first quarter of 2014." What does that mean? Make a list of 10 possible companies we'd like to talk to? It isn't very concrete. I am sure in 2 years AMBS will be flying!! But, I'm not sure yet how well we'll be doing in 2 months.
mutai: I saw this email from Gerald yesterday. It helps...some. But you would think the head of the Alzheimer's Department at Boston U who is also consulting with us on LymPro for concussions would be familiar with Gerald's statements about getting FDA approval in a couple of years. His statement shows he does not take LymPro for AD seriously. That is what frustrates some of us. Gerald has been promoting LymPro for AD a BREAKTHROUGH diagnostic tool that is going to help revolutionize the Alzheimer's industry!! I would have thought Dr. Sterns would have known that.
Hnbadger: I have been restricted to one post per day on IHub so I cannot answer your questions there. I am not informed enough to speak to this bill you inquired about. Perhaps there are others here on the mb that could better enlighten us. As for your question about Dr. Robert Stern's reference to the FDA not approving an AD blood test for 5 to 10 years...I called and spoke with Aimee the IR person at AMBS. She is new there and I filled her in on our frustration over the obvious contradiction of Stern's time frames and those Gerald has given us. She said she will talk to Gerald and get back with me. If Hnbadger doesn't post on Yahoo, maybe someone else could inform him on IHub what I have just said.
pedro: There will be a Reverse Split that will affect the share price, but using pre-RS numbers here are my guesses. There is no chance of bankruptcy in the next 12 months since we have enough cash (using the Lincoln Park 20 million) to last longer than 12 months. If everything went wrong for us I'd say we could be at .05 cents in one year. I'd give that a 5% chance of happening. If things go conservatively well, I'd say we'd be above .25 cents. If things go moderately well, we'd be above .60 cents. If things go real well we could hit $1.50 in 12 months. My gut tells me we'll be in the .70 cent to $1.20 cent range in 12 months. These are all guesses, of course. I suppose there is a chance if we ran the gamut on everything that we could be above $2 or $3 in 12 months, but I'd give that maybe a 5% chance.
Thanks, Gary. I wonder why Gerald didn't tell us that CLIA Regulations prevented him from reporting data at this point? I think that would have prevented our consternation over why the data wasn't presented. In a Press Release where you are trying to excite shareholders, the words you use matter! Fortunately, you've cleared it up . Thanks, again!
belle: kerry fairy is fairly miserable, don't you think? For some reason he seems to be seeking for recognition for his researching ability. Maybe he's an unemployed PhD?
mkerryfuller: You are one unhappy fellow...in spite of the research feather you've conspicuously placed in your cap!